Executive Director of the Harvard Stem Cell Institute
Brock Reeve, a graduate of Yale and the Harvard Business School, is
Executive Director of the Harvard Stem Cell Institute. In partnership
with the Faculty Directors, he has overall responsibility for the
operations and strategy of the institute whose mission is to use stem
cells, both as tools and as therapies, to understand and treat the root
causes of leading degenerative diseases.
HSCI is comprised of the schools of Harvard University and all its
affiliated hospitals and research institutions. The institute currently
has 60 principal faculty and 70 affiliated faculty. Under the
leadership of the Executive Committee, HSCI invests in scientific
research in three main areas – seed grants, core facilities and
large-scale disease programs. Beyond the science, the institute
also has programs to address ethics and public policy issues, to
provide lab experiences for undergraduates, to educate high school
science teachers, science journalists and the public at large.
Brock comes to this role from the commercial sector with extensive
experience in both management consulting and operations for
technology-based companies, with a focus on life sciences.
Brock’s business career started with the Boston Consulting
Group. Prior to Harvard, Brock was COO and Managing Director of
Life Science Insights, an IDC company, a consulting and market research
firm specializing in information technology in life sciences.
Previously, Brock was an Associate Partner in the Pharmaceutical and
Life Sciences practice in IBM’s Business Consulting Services
group, working with biotech and pharmaceutical clients on issues
ranging from R&D portfolios to operations strategies. Brock
also has had hands-on operational responsibility in product management
and marketing roles in software start-ups as well as additional
experience in IT and the healthcare/life science market as the
Healthcare Practice Director at Viant Corp. and a Principal at SRI
Consulting, where his clients included some of the leading
pharmaceutical, biotechnology and medical device companies.